Trial site
Twoja Przychodnia Poznanskie Centrum Medyczne Sp. z o.o.
- 40running trials
- 20closed trials
The trials here
What the 60 trials at this site are about, from their registry records.
- Conditions
- Crohn's disease10 trials
- Ulcerative colitis10 trials
- Lupus (SLE)7 trials
- Psoriatic arthritis7 trials
- Psoriasis6 trials
- Sjögren's disease5 trials
- Atopic dermatitis (eczema)4 trials
- Myasthenia gravis3 trials
- Rheumatoid arthritis3 trials
- Systemic sclerosis (scleroderma)3 trials
- Dermatomyositis and polymyositis (myositis)2 trials
- Multiple sclerosis2 trials
- and 4 more
- Phase
- Phase 335 trials
- Phase 222 trials
- Phase 1/21 trial
- Phase 2/31 trial
- Phase 41 trial
- Status
- Completed20 trials
- Recruiting18 trials
- Active, not recruiting17 trials
- Not yet recruiting5 trials
- Lead sponsor
- Janssen Research & Development, LLC6 trials
- Abivax S.A.3 trials
- MoonLake Immunotherapeutics AG3 trials
- Pfizer3 trials
- Takeda3 trials
- and 36 more
Running trials
Not yet recruiting
Recruiting
A Phase 2b Study of the Effects of Camoteskimab in Adults with Moderate-to-Severe Atopic Dermatitis
Recruiting
A Phase 3 Study to Evaluate Claseprubart in Adults With Generalized Myasthenia Gravis (EMERGE)
Recruiting
Active, not recruiting
A Phase 2 Study to Evaluate Povetacicept in Adults With Generalized Myasthenia Gravis
Recruiting
Recruiting
Recruiting
Recruiting
A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis
Recruiting
A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis
Recruiting
Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis
Recruiting
A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus
Not yet recruiting
Recruiting
Phase 3 Study of Telitacicept in Active Primary Sjögren's Disease
Recruiting
Active, not recruiting
Recruiting
Recruiting
A clinical study of MK-7240 for the treatment of Crohn’s disease (MK-7240-008)
Recruiting
A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata
Active, not recruiting
Active, not recruiting
Active, not recruiting
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines
Recruiting
A Long-term Extension Study of Dazodalibep in Participants With Sjögren's Syndrome (SS)
Active, not recruiting
Tibulizumab Systemic Sclerosis Understanding and Response Evaluation (TibuSURE)
Recruiting
Recruiting
Recruiting
Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease
Active, not recruiting
Enrolling by invitation
Long-term Safety and Tolerability of Cenerimod in Adults With Systemic Lupus Erythematosus
Recruiting
A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease
Recruiting
Recruiting
Active, not recruiting
Recruiting
Active, not recruiting
Active, not recruiting
Active, not recruiting
Active, not recruiting
Enrolling by invitation
Active, not recruiting
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
- Lupus (SLE)4 recruiting
- Ulcerative colitis4 recruiting
- Crohn's disease3 recruiting
- Myasthenia gravis3 recruiting
- Atopic dermatitis (eczema)2 recruiting
- Dermatomyositis and polymyositis (myositis)2 recruiting
- Multiple sclerosis2 recruiting
- Psoriatic arthritis2 recruiting
- Primary biliary cholangitis1 recruiting
- Psoriasis1 recruiting
- Sjögren's disease1 recruiting
Closed trials
Completed
Completed
Completed
Active, not recruiting
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
BP11 Versus EU-Approved Xolair® in Patients With Chronic Spontaneous Urticaria
Completed
A Study to Evaluate MORF-057 in Adults With Moderately to Severely Active UC
Completed
ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1
Completed
The WILLOW Study With M5049 in SLE and CLE (SCLE and/or DLE) (WILLOW)
Active, not recruiting
Completed
Active, not recruiting
Completed
Site data: EU CTIS (euclinicaltrials.eu)Updated 19 Nov 2026